more information

Category:

Biologically Active Peptides

reference

1. D.E. Jones and C.L. Bevins, FEBS Lett., 315, 187 (1993). (Original;mRNA Seq.)
2. E.M. Porter, M.A. Poles, J.S. Lee, J. Naitoh, C.L. Bevins, and T. Ganz, FEBS Lett., 434, 272 (1998). (Endogenous Form)
3. B. Ericksen, Z. Wu, W. Lu, and R.I. Lehrer, Antimicrob. Agents Chemother., 49, 269 (2005). (Pharmacol.; No Antibacterial Activity)
4. J. Wehkamp, K. Schmidt, K.R. Herrlinger, S. Baxmann, S. Behling, C. Wohlschläger, A.C. Feller, E.F. Stange, and K. Fellermann, J. Clin. Pathol., 56, 352 (2003). (Pharmacol.; Enhanced Expression in Helicobacter pylori Infection)
5. E. Hazrati, B. Galen, W. Lu, W. Wang, Y. Ouyang, M.J. Keller, R.I. Lehrer. and B.C. Herold, J. Immunol., 177, 8658 (2006). (Pharmacol.; Inhibition of Herpes Simplex Virus Infection)
6. M. Doss, M.R. White, T. Tecle, D. Gantz, E.C. Crouch, G. Jung, P. Ruchala, A.J. Waring, R.I. Lehrer, and K.L. Hartshorn, J. Immunol., 182, 7878 (2009). (Pharmacol.; Influenza A Virus Neutralizing Activity)
7. M.J. Koslowski, J. Beisner, E.F. Stange, and J. Wehkamp, Int. J. Med. Microbiol., 300, 34 (2010). (Minireview; Antimicrobial Host Defense in Small Crohn's Disease)
8. M.E. Klotman, A. Rapista, N. Teleshova, A. Micsenyi, G.A. Jarvis, W. Lu, E. Porter, and T.L. Chang, J. Immunol., 180, 6176 (2008). (Pharmacol.; Enhancement of HIV Infectivity)
9. R.I. Lehrer and T. Ganz, Ann. N. Y. Acad. Sci., 797, 228 (1996). (Review)
10. M. Zasloff, Nature, 415, 389 (2002). (Review)